- Home
- ITIC vs MIST Comparison
ITIC vs MIST Comparison
Compare ITIC & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ITIC | MIST |
|---|---|---|
| Founded | 1972 | 2003 |
| Country | United States | Canada |
| Employees | 574 | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 546.1M | 136.9M |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ITIC | MIST |
|---|---|---|
| Price | $287.45 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 48.4K | ★ 1.6M |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.43% | N/A |
| EPS Growth | ★ 13.02 | N/A |
| EPS | ★ 10.93 | N/A |
| Revenue | ★ $272,755,000.00 | N/A |
| Revenue This Year | N/A | $2,915.14 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.36 | ★ N/A |
| Revenue Growth | ★ 5.60 | N/A |
| 52 Week Low | $209.75 | $1.00 |
| 52 Week High | $297.99 | $3.06 |
Technical Indicators
Market Signals| Indicator | ITIC | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 54.26 | 39.37 |
| Support Level | $275.85 | $1.01 |
| Resistance Level | $296.60 | $1.42 |
| Average True Range (ATR) | 8.19 | 0.07 |
| MACD | -0.72 | -0.01 |
| Stochastic Oscillator | 55.88 | 9.26 |
Price Performance
Historical ComparisonAbout ITIC Investors Title Company
Investors Title Co operates in the title insurance and exchange services sectors. The Company has two reportable segments. The Company's primary business activity, and one of its reportable operating segments, is the issuance of residential and commercial title insurance through ITIC and NITIC. The company's second reportable operating segment is providing tax-deferred real property exchange services through its subsidiaries, Investors Title Exchange Corporation (ITEC) and Investors Title Accommodation Corporation (ITAC).
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.